Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies
Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies
复制标题
DOI：
10.1002/jmv.27310
复制
发表时间：
2021-09-08
影响因子：
12.7
通讯作者：
Ramirez, Eugenio
中科院分区：
文献类型：
--
作者：
Fernandez, Jorge;Bruneau, Nicole;Ramirez, Eugenio
疫苗接种产生针对SARS-CoV-2的中和免疫应答。基因组监测显示出现了在刺突（中和抗体的主要靶标）中具有突变的变体。为了了解这些变体的影响，我们报告了44名接受两剂CoronaVac疫苗（一种灭活SARS-CoV-2疫苗）的个体对α，γ和D 614 G SARS-CoV-2变体的中和效力。在CoronaVac第二次给药后60天收集的血浆样品通过SARS-CoV-2的三种感染性变体在Vero E6细胞中的细胞病变效应的减少进行分析。血浆显示α（几何平均滴度[GMT] = 18.5）和γ（GMT = 10.0）变体的中和作用低于D 614 G（GMT = 75.1）变体。分别在31.8%和59.1%的血浆中未检测到针对α和γ变体的有效中和。这些发现表明α和γ变体可以逃避疫苗接种引起的抗体的中和。对病毒变异体进行强有力的基因组和生物学监测有助于制定控制SARS-CoV-2的有效策略。
Vaccination generates a neutralizing immune response against SARS-CoV-2. The genomic surveillance is showing the emergence of variants with mutations in spike, the main target of neutralizing antibodies. To understand the impact of these variants, we report the neutralization potency against alpha, gamma, and D614G SARS-CoV-2 variants in 44 individuals that received two doses of CoronaVac vaccine, an inactivated SARS-CoV-2 vaccine. Plasma samples collected at 60 days after the second dose of CoronaVac were analyzed by the reduction of cytopathic effect in Vero E6 cells with the three infectious variants of SARS-CoV-2. Plasma showed lower neutralization with alpha (geometric mean titer [GMT] = 18.5) and gamma (GMT = 10.0) variants than with D614G (GMT = 75.1) variant. Efficient neutralization against the alpha and gamma variants was not detected in 31.8% and 59.1% of plasma, respectively. These findings suggest the alpha and gamma variants could escape from neutralization by antibodies elicited by vaccination. Robust genomic and biological surveillance of viral variants could help to develop effective strategies for the control of SARS-CoV-2.